Evaluation of the antitumor effects and mechanisms of PF00299804, a pan-HER inhibitor, alone or in combination with chemotherapy or targeted agents in gastric cancer

Molecular Cancer Therapeutics

Volumn 11, Issue 2, 2012, Pages 439-451

  Nam, Hyun Jin ^a   Ching, Keith A ^b   Kan, Julie ^b   Kim, Hwang Phill ^a   Han, Sae Won ^a   Im, Seock Ah ^a   Kim, Tae You ^a   Christensen, James G ^b   Oh, Do Youn ^a   Bang, Yung Jue ^a  

^a Seoul National University Hospital   (South Korea)

^b PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AFATINIB; CANERTINIB; CISPLATIN; DACOMITINIB; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FIGITUMUMAB; FLUOROURACIL; GEFITINIB; HETERODIMER; LAPATINIB; MITOGEN ACTIVATED PROTEIN KINASE; N (2,3 DIHYDROXYPROPOXY) 3,4 DIFLUORO 2 (2 FLUORO 4 IODOANILINO)BENZAMIDE; PROTEIN KINASE B; STAT3 PROTEIN; TRASTUZUMAB;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BAGG ALBINO MOUSE; CANCER CELL; CANCER MODEL; CONTROLLED STUDY; FEMALE; G1 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PHOSPHORYLATION; PRIORITY JOURNAL; STOMACH CANCER;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; DRUG SYNERGISM; FEMALE; G1 PHASE; HUMANS; MICE; MICE, SCID; MOLECULAR STRUCTURE; PROTEIN KINASE INHIBITORS; QUINAZOLINONES; RECEPTOR, ERBB-2; STOMACH NEOPLASMS; TIME FACTORS; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84863169318     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-11-0494     Document Type: Article

References (50)

1. Bazley LA, Gullick WJ. The epidermal growth factor receptor family. Endocr Relat Cancer 2005;12 Suppl 1:S17-27. (Pubitemid 41395411)
2. Klapper LN, Glathe S, Vaisman N, Hynes NE, Andrews GC, Sela M, et al. The ErbB-2/HER2 oncoprotein of human carcinomas may function solely as a shared coreceptor for multiple stroma-derived growth factors. Proc Natl Acad Sci U S A 1999;96:4995-5000.
3. Peles E, Bacus SS, Koski RA, Lu HS, Wen D, Ogden SG, et al. Isolation of the neu/HER-2 stimulatory ligand: a 44 kd glycoprotein that induces differentiation of mammary tumor cells. Cell 1992;69:205-16.
4. King CR, Borrello I, Bellot F, Comoglio P, Schlessinger J. Egf binding to its receptor triggers a rapid tyrosine phosphorylation of the erbB-2 protein in the mammary tumor cell line SK-BR-3. EMBO J 1988;7: 1647-51.
5. Klapper LN, Kirschbaum MH, Sela M, Yarden Y. Biochemical and clinical implications of the ErbB/HER signaling network of growth factor receptors. Adv Cancer Res 2000;77:25-79. (Pubitemid 29439302)
6. Tzahar E, Waterman H, Chen X, Levkowitz G, Karunagaran D, Lavi S, et al. A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor. Mol Cell Biol 1996;16:5276-87. (Pubitemid 26315047)
7. Karunagaran D, Tzahar E, Beerli RR, Chen X, Graus-Porta D, Ratzkin BJ, et al. ErbB-2 is a common auxiliary subunit of NDF and EGF receptors: implications for breast cancer. EMBO J 1996;15:254-64. (Pubitemid 26029205)
8. Citri A, Skaria KB, Yarden Y. The deaf and the dumb: the biology of ErbB-2 and ErbB-3. Exp Cell Res 2003;284:54-65. (Pubitemid 36342255)
9. Monsey J, Shen W, Schlesinger P, Bose R. Her4 and Her2/neu tyrosine kinase domains dimerize and activate in a reconstituted in vitro system. J Biol Chem 2010;285:7035-44.
10. Kim MA, Lee HS, Lee HE, Jeon YK, Yang HK, Kim WH. EGFR in gastric carcinomas: prognostic significance of protein overexpression and high gene copy number. Histopathology 2008;52:738-46. (Pubitemid 351600058)
11. León-Chong J, Lordick F, Kang YK, Park SR, Bang YJ, Sawaki A, et al. HER2 positivity in advanced gastric cancer is comparable to breast cancer. J Clin Oncol 2007 ASCO Annual Meeting Proceedings Part I. 25:18s, 2007 (suppl; abstr 15057).
12. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010;376:687-97.
13. Kim JW, Kim HP, Im SA, Kang S, Hur HS, Yoon YK, et al. The growth inhibitory effect of lapatinib, a dual inhibitor of EGFR and HER2 tyrosine kinase, in gastric cancer cell lines. Cancer Lett 2008;272: 296-306.
14. Kim HP, Han SW, Kim SH, Im SA, Oh DY, Bang YJ, et al. Combined lapatinib and cetuximab enhance cytotoxicity against gefitinib-resistant lung cancer cells. Mol Cancer Ther 2008;7:607-15.
15. Kim HP, Yoon YK, Kim JW, Han SW, Hur HS, Park J, et al. Lapatinib, a dual EGFR and HER2 tyrosine kinase inhibitor, downregulates thymidylate synthase by inhibiting the nuclear translocation of EGFR and HER2. PLoS One 2009;4:e5933.
16. GlaxoSmithKline. Lapatinib Optimization Study in ErbB2 (HER2) positive gastric cancer: aphase III global, blinded study designed to evaluate clinical endpoints and safety of chemotherapy plus lapatinib [monograph on the Internet]. Bethesda, MD: NIH; 2011. [Cited Oct. 2011]. Available from: http://clinicaltrials.gov/ct2/show/NCT00680901.
17. Zhang XL, Yang YS, Xu DP, Qu JH, Guo MZ, Gong Y, et al. Comparative study on overexpression of HER2/neu and HER3 in gastric cancer. World J Surg 2009;33:2112-8.
18. Lee-Hoeflich ST, Crocker L, Yao E, Pham T, Munroe X, Hoeflich KP, et al. A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy. Cancer Res 2008;68:5878-87.
19. Engelman JA, Zejnullahu K, Gale CM, Lifshits E, Gonzales AJ, Shimamura T, et al. PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib. Cancer Res 2007;67:11924-32.
20. Gonzales AJ, Hook KE, Althaus IW, Ellis PA, Trachet E, Delaney AM, et al. Antitumor activity and pharmacokinetic properties of PF- 00299804, a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor. Mol Cancer Ther 2008;7:1880-9.
21. Boyer MJ, Blackhall FH, Park K, Barrios CH, Krzakowski MJ, Taylor I, et al. Efficacy and safety of PF299804 versus erlotinib (E): a global, randomized phase II trial in patients (pts) with advanced non-small cell lung cancer (NSCLC) after failure of chemotherapy (CT). J Clin Oncol 28:18s, 2010 (suppl; abstr LBA7523).
22. Wong TW, Lee FY, Yu C, Luo FR, Oppenheimer S, Zhang H, et al. Preclinical antitumor activity of BMS-599626, a pan-HER kinase inhibitor that inhibits HER1/HER2 homodimer and heterodimer signaling. Clin Cancer Res 2006;12:6186-93. (Pubitemid 44703785)
23. Nam HJ, Kim HP, Yoon YK, Hur HS, Song SH, Kim MS, et al. Antitumor activity of HM781-36B, an irreversible Pan-HER inhibitor, alone or in combination with cytotoxic chemotherapeutic agents in gastric cancer. Cancer Lett 2011;302:155-65.
24. Seoul National University Hospital. PF-00299804 monotherapy in patients with HER-2 positive advanced gastric cancer. [monograph on the Internet]. Bethesda, MD: NIH; 2010. [Cited Oct. 2011]. Available from: http:// clinicaltrials.gov/ct2/show/NCT01152853.
25. Pao W, Chmielecki J. Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer. Nat Rev Cancer 2010;10:760-74.
26. Vilar E, Perez-Garcia J, Tabernero J. Pushing the envelope in them TOR pathway: the second generation of inhibitors. Mol Cancer Ther 2011; 10:395-403.
27. Ku JL, Park JG. Biology of SNU cell lines. Cancer Res Treat 2005;37: 1-19.
28. Fujimoto-Ouchi K, Sekiguchi F, Yasuno H, Moriya Y, Mori K, Tanaka Y. Antitumor activity of trastuzumab in combination with chemotherapy in human gastric cancer xenograft models. Cancer Chemother Pharmacol 2007;59:795-805. (Pubitemid 46440603)
29. Ritz C, Streibig JC. Bioassay analysis using R. J Stat Software 2005;12.
30. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984;22:27-55.
31. Erlichman C, Boerner SA, Hallgren CG, Spieker R, Wang XY, James CD, et al. The HER tyrosine kinase inhibitor CI1033 enhances cytotoxicity of 7-ethyl-10-hydroxycamptothecin and topotecan by inhibiting breast cancer resistance protein-mediated drug efflux. Cancer Res 2001;61:739-48. (Pubitemid 32128641)
32. Bengtsson H, Wirapati, P, Speed TP. A single-array preprocessing method for estimating full-resolution raw copy numbers from all Affymetrix genotyping arrays including Genome Wide SNP 5 & 6. Bio-informatics 2009;25:2149-56.
33. Lee KW, Kim JH, Park JH, Kim HP, Song SH, Kim SG, et al. Antitumor activity of SK-7041, a novel histone deacetylase inhibitor, in human lung and breast cancer cells. Anticancer Res 2006;26:3429-38. (Pubitemid 44701519)
34. Yoon YK, Kim HP, Han SW, Hur HS, Oh do Y, Im SA, et al. Combination of EGFR and MEK1/2 inhibitor shows synergistic effects by suppressing EGFR/HER3-dependent AKT activation in human gastric cancer cells. Mol Cancer Ther 2009;8:2526-36.
35. Wang J, Liu W, Zhao Q, Qi Q, Lu N, Yang Y, et al. Synergistic effect of 5-fluorouracil with gambogic acid on BGC-823 human gastric carcinoma. Toxicology 2009;256:135-40.
36. Osawa K. Gene polymorphisms and chemotherapy in non-small cell lung cancer. Zhongguo Fei Ai Za Zhi 2009;12:837-40.
37. Pietras RJ, Poen JC, Gallardo D, Wongvipat PN, Lee HJ, Slamon DJ. Monoclonal antibody to HER-2/neureceptor modulates repair of radiation- induced DNA damage and enhances radiosensitivity of human breast cancer cells overexpressing this oncogene. Cancer Res 1999; 59:1347-55. (Pubitemid 29136268)
38. Kunii K, Davis L, Gorenstein J, Hatch H, Yashiro M, Di Bacco A, et al. FGFR2-amplified gastric cancer cell lines require FGFR2 and Erbb3 signaling for growth and survival. Cancer Res 2008;68: 2340-8. (Pubitemid 351521808)
39. Dean-Colomb W, Esteva FJ. Her2-positive breast cancer: herceptin and beyond. Eur J Cancer 2008;44:2806-12.
40. Ono M, Hirata A, Kometani T, Miyagawa M, Ueda S, Kinoshita H, et al. Sensitivity to gefitinib (Iressa, ZD1839) in non-small cell lung cancer cell lines correlates with dependence on the epidermal growth factor (EGF) receptor/extracellular signal-regulated kinase 1/2 and EGF receptor/Akt pathway for proliferation. Mol Cancer Ther 2004;3: 465-72. (Pubitemid 39193724)
41. Patel D, Bassi R, Hooper A, Prewett M, Hicklin DJ, Kang X. Antiepidermal growth factor receptor monoclonal antibody cetuximab inhibits EGFR/HER-2 heterodimerization and activation. Int J Oncol 2009;34:25-32.
42. -/-smooth muscle cell proliferation. Possible treatment options for TSC and LAM. PLoS One 2008;3:e3558.
43. Hirata A, Hosoi F, Miyagawa M, Ueda S, Naito S, Fujii T, et al. HER2 overexpression increases sensitivity to gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, through inhibition of HER2/ HER3 heterodimer formation in lung cancer cells. Cancer Res 2005; 65:4253-60. (Pubitemid 40775664)
44. Ejskjaer K, Sorensen BS, Poulsen SS, Forman A, Nexo E, Mogensen O. Expression of the epidermal growth factor system in endometrioid endometrial cancer. Gynecol Oncol 2007;104:158-67. (Pubitemid 46054118)
45. Campiglio M, Ali S, Knyazev PG, Ullrich A. Characteristics of EGFR family-mediated HRG signals in human ovarian cancer. J Cell Biochem 1999;73:522-32. (Pubitemid 29256941)
46. Turke A, Zejnullahu K, Wu Y, Song Y, Dias-Santagata D, Lifshits E, et al. Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. Cancer Cell 2010;17:77-88.
47. Lee S, Yang W, Lan KH, Sellappan S, Klos K, Hortobagyi G, et al. Enhanced sensitization to taxol-induced apoptosis by herceptin pretreatment in ErbB2-overexpressing breast cancer cells. Cancer Res 2002;62:5703-10. (Pubitemid 35204725)
48. Wainberg ZA, Anghel A, Desai AJ, Ayala R, Luo T, Safran B, et al. Lapatinib, a dual EGFR and HER2 kinase inhibitor, selectively inhibits HER2-amplified human gastric cancer cells and is synergistic with trastuzumab in vitro and in vivo. Clin Cancer Res 2010; 16:1509-19.
49. Browne BC, Crown J, Venkatesan N, Duffy MJ, Clynes M, Slamon D, et al. Inhibition of IGF1R activity enhances response to trastuzumab in HER-2-positive breast cancer cells. Ann Oncol 2011;22:68-73.
50. Miller TW, Forbes JT, Shah C, Wyatt SK, Manning HC, Olivares MG, et al. Inhibition of mammalian target of rapamycin is required for optimal antitumor effect of HER2 inhibitors against HER2-overexpressing cancer cells. Clin Cancer Res 2009;15:7266-76.